register

News & Trends - Pharmaceuticals

Menarini completes acquisition of Stemline Therapeutics

Health Industry Hub | June 15, 2020 |

Pharma News: Menarini Group, a privately held pharmaceutical and diagnostics company, completed the acquisition of Stemline Therapeutics, a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel oncology therapeutics.

The $677 million transaction strengthens Menarini’s oncology portfolio with the addition of both commercial and clinical-stage assets.

Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and paediatric patients, two years or older, following the approval by the United States Food and Drug Administration (FDA) in December 2018.

Elcin Barker Ergun, CEO of Menarini Group, commented, “We are very excited to complete the acquisition of Stemline and to welcome their accomplished team to Menarini. The addition of ELZONRIS, which has potential to treat many other malignancies, as well as the other attractive pipeline assets augments our research and development capabilities and will accelerate our efforts to deliver novel oncology therapeutics to patients in need.”

ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123), a target present on a wide range of malignancies. In parallel, Stemline has been evaluating ELZONRIS in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others. Stemline’s additional pipeline candidates include felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing) and SL-1001 (RET kinase inhibitor, IND-enabling studies ongoing).

Register & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.


Digital & Innovation

Liverpool Hospital partners with Microsoft in cardiology care

Health Industry Hub | December 8, 2023 |

Digital & Innovation: Liverpool Hospital and tech giant Microsoft have joined forces in a collaboration aimed at enhancing the way […]

More


News & Trends - MedTech & Diagnostics

Sydney cancer centre welcomes new medical technology ahead of grand opening

Sydney cancer centre welcomes new medical technology ahead of grand opening

Health Industry Hub | December 8, 2023 |

MedTech & Diagnostics News: A $52 million integrated cancer treatment facility in Campbelltown, located in south-western Sydney, is swiftly advancing […]

More


News & Trends - Pharmaceuticals

Largest pharmacy retailer ASX debut via wholesaler takeover sparks industry concerns - Chemist Warehouse, Sigma Healthcare

Largest pharmacy retailer ASX debut via wholesaler takeover sparks industry concerns

Health Industry Hub | December 8, 2023 |

Pharma News: Australia’s largest pharmacy retailer is gearing up for a significant move as it eyes a listing on the […]

More


News & Trends - Pharmaceuticals

Eli Lilly's rheumatoid arthritis medicine to slow progression of type 1 diabetes, say Aussie researchers

Eli Lilly’s rheumatoid arthritis medicine to slow progression of type 1 diabetes, say Aussie researchers

Health Industry Hub | December 8, 2023 |

Pharma News: Australian researchers have shown that a commonly prescribed rheumatoid arthritis medicine can stop the progression of type 1 […]

More


This content is copyright protected. Please subscribe to gain access.